In last trading session, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) saw 0.36 million shares changing hands with its beta currently measuring 2.62. Company’s recent per share price level of $16.97 trading at -$0.45 or -2.58% at ring of the bell on the day assigns it a market valuation of $459.67M. That closing price of ARCT’s stock is at a discount of -165.17% from its 52-week high price of $45.00 and is indicating a premium of 15.73% from its 52-week low price of $14.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.39 million shares which gives us an average trading volume of 428.56K if we extend that period to 3-months.

For Arcturus Therapeutics Holdings Inc (ARCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.45 in the current quarter.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information

Upright in the red during last session for losing -2.58%, in the last five days ARCT remained trading in the red while hitting it’s week-highest on Friday, 01/31/25 when the stock touched $16.97 price level, adding 5.46% to its value on the day. Arcturus Therapeutics Holdings Inc’s shares saw a change of 0.00% in year-to-date performance and have moved -0.88% in past 5-day. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) showed a performance of 2.35% in past 30-days. Number of shares sold short was 5.04 million shares which calculate 11.98 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 10.58 to the stock, which implies a fall of -60.4% to its current value. Analysts have been projecting 10.58 as a low price target for the stock while placing it at a high target of 10.58. It follows that stock’s current price would jump 37.65% in reaching the projected high whereas dropping to the targeted low would mean a gain of 37.65% for stock’s current value.

Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts

Statistics highlight that Arcturus Therapeutics Holdings Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -27.66% of value to its shares in past 6 months, showing an annual growth rate of -11.56% while that of industry is 16.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 2.53% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 44.64M for the same. And 6 analysts are in estimates of company making revenue of 56.24M in the next quarter. Company posted 33.99M and 38.01M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 12.40% during past 5 years.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s Major holders

Insiders are in possession of 8.46% of company’s total shares while institution are holding 89.67 percent of that, with stock having share float percentage of 97.95%. Investors also watch the number of corporate investors in a company very closely, which is 89.67% institutions for Arcturus Therapeutics Holdings Inc that are currently holding shares of the company. FEDERATED HERMES, INC. is the top institutional holder at ARCT for having 4.69 million shares of worth $114.3 million. And as of 2024-06-30, it was holding 17.4067 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 2.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.8262 of outstanding shares, having a total worth of $64.52 million.

On the other hand, Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 2.44 shares of worth $41.34 million or 8.99% of the total outstanding shares. The later fund manager was in possession of 2.2 shares on Oct 31, 2024 , making its stake of worth around $37.3 million in the company or a holder of 8.11% of company’s stock.